Free Trial
NASDAQ:XFOR

X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis

X4 Pharmaceuticals logo
$3.75 -0.56 (-12.99%)
Closing price 05/1/2025 04:00 PM Eastern
Extended Trading
$3.84 +0.09 (+2.40%)
As of 05/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About X4 Pharmaceuticals Stock (NASDAQ:XFOR)

Key Stats

Today's Range
$3.70
$4.25
50-Day Range
$3.75
$13.09
52-Week Range
$3.70
$36.00
Volume
263,792 shs
Average Volume
91,937 shs
Market Capitalization
$651.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$85.00
Consensus Rating
Buy

Company Overview

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

X4 Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

XFOR MarketRank™: 

X4 Pharmaceuticals scored higher than 77% of companies evaluated by MarketBeat, and ranked 77th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    X4 Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    X4 Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about X4 Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($0.68) to ($0.51) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of X4 Pharmaceuticals is -41.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of X4 Pharmaceuticals is -41.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    X4 Pharmaceuticals has a P/B Ratio of 12.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.24% of the float of X4 Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    X4 Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in X4 Pharmaceuticals has recently increased by 8.91%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    X4 Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    X4 Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.24% of the float of X4 Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    X4 Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in X4 Pharmaceuticals has recently increased by 8.91%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    X4 Pharmaceuticals has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for X4 Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    Only 3 people have searched for XFOR on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, X4 Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.62% of the stock of X4 Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about X4 Pharmaceuticals' insider trading history.
Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XFOR Stock News Headlines

Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.
X4 Pharmaceuticals Q1 2025 Earnings Preview
X4 Pharmaceuticals Analyst Ratings
Earnings Preview For X4 Pharmaceuticals
See More Headlines

XFOR Stock Analysis - Frequently Asked Questions

X4 Pharmaceuticals' stock was trading at $22.0080 at the beginning of the year. Since then, XFOR stock has decreased by 83.0% and is now trading at $3.75.
View the best growth stocks for 2025 here
.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) posted its quarterly earnings results on Tuesday, March, 25th. The company reported ($6.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.10) by $0.90. The business had revenue of $1.43 million for the quarter, compared to the consensus estimate of $1.07 million.
Read the conference call transcript
.

X4 Pharmaceuticals's stock reverse split before market open on Monday, April 28th 2025. The 1-30 reverse split was announced on Thursday, April 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that X4 Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Intel (INTC).

Company Calendar

Last Earnings
3/25/2025
Today
5/01/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XFOR
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$85.00
High Stock Price Target
$120.00
Low Stock Price Target
$45.00
Potential Upside/Downside
+2,166.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-101,170,000.00
Pretax Margin
-1,484.77%

Debt

Sales & Book Value

Annual Sales
$2.56 million
Price / Cash Flow
N/A
Book Value
$0.31 per share
Price / Book
12.10

Miscellaneous

Free Float
167,783,000
Market Cap
$651.23 million
Optionable
Optionable
Beta
0.58
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:XFOR) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners